Rob Michael, Chief Executive Officer of AbbVie, posted on LinkedIn:

“Today, the U.S. FDA announced accelerated approval for AbbVie’s new medicine to treat certain types of advanced non-squamous non-small cell lung cancer (NSCLC). There is a need for new therapies for patients with difficult to treat tumors like NSCLC given the limited treatment options.

I am proud of our employees’ strong commitment to patients and their extensive efforts to make this approval possible.

Learn more here.”

Rob Michael Announces FDA Approval of AbbVie’s New NSCLC Therapy

“Today, the U.S. FDA announced accelerated approval for AbbVie’s new medicine to treat certain types of advanced non-squamous non-small cell lung cancer (NSCLC). There is a need for new therapies for patients with difficult to treat tumors like NSCLC given the limited treatment options.

I am proud of our employees’ strong commitment to patients and their extensive efforts to make this approval possible.

Learn more here.”